Archive — US — techcrunch
BioticsAI, Battlefield 2023, gains FDA approval for its AI-powered fetalultrasound product
BioticsAI, winner of TechCrunch Disrupt Battlefield 2023, has received FDA approval for its AI-powered software that detects fetal abnormalities in ultrasound images. Founded by Robhy Bustami, the technology aims to improve prenatal outcomes, particularly among high-risk demographics, using computer vision to enhance ultrasound quality assessment and reporting.
Key points
- BioticsAI wins TechCrunch Disrupt Battlefield 2023.
- Received FDA clearance for AI software to detect fetal abnormalities.
- Founded by Robhy Bustami, inspired by family’s obstetrician background.
- Software uses computer vision AI to improve ultrasound image quality.
- Addresses poor prenatal outcomes in the U.S., especially among Black women.
- Company took under three years to complete the FDA approval process, emphasizing collaboration among engineering, clinical, and regulatory teams.
Why it matters
- The news relates to ongoing concerns regarding healthcare disparities, particularly in maternal health.
- Reflects the trend of increasing AI applications in healthcare, improving diagnostics and patient outcomes.
- Aligns with the growing demand for healthcare technology and innovation, especially post-COVID-19.
BioticsAI's FDA approval marks a significant step in addressing maternal health disparities, showcasing how AI can enhance prenatal care and promising further advancements in healthcare technology.